accessibility menu, dialog, popup

UserName
Viewing profile as user:

Hydrocarbons

Organic compounds that consists entirely of hydrogen and carbon elements usually organized in a chain; some may have a cyclic structure. Includes hydrocarbons that have additional functional groups such as aromatic rings.
Unsaturated hydrocarbons (5)

Filtered Search Results

Products from some of our suppliers do not display in filtered search results. Please clear all filters to see these products.

Narrow Results

Narrow Results

category

brands

  • (5)

special interests

  • (5)
Search Within Results
Keyword Search:
1 – 5 of 5 results
1

Medchemexpress LLC Acetamide, 2-[[7-(3,4-dimethoxyphenyl)-2-quinoxalinyl)amino]-N-methyl- | 1513879-21-4 | 99.9% | 352.39 | 5 MG
SDP

BQR-695 is a PI4KIIIβ inhibitor, active against both human and *Plasmodium* variants of PI4KIIIβ. It effectively inhibits PI4KIIIβ function, leading to depletion of intracellular PI4P, and shows no toxicity against mature red blood cells. It induces schizont-stage arrest and exhibits cross-resistance with imidazopyrazine-resistant lines.

  • Inhibits human PI4KIIIβ with an IC50 of 80 nM
  • Inhibits *Plasmodium* PI4KIIIβ with an IC50 of 3.5 nM
  • Causes GFP-PHOsh2 to redistribute to parasite plasma membrane
  • No toxicity against mature red blood cells
  • Induces schizont-stage arrest
  • Exhibits cross-resistance with imidazopyrazine-resistant lines

ENCOMPASS_PREFERRED
2

Medchemexpress LLC DI-591 | 2245887-38-9 | 98.4% | 585.80 | 10 MG
SDP

DI-591 is a potent, high-affinity, and cell-permeable inhibitor of the DCN1-UBC12 interaction. It selectively inhibits neddylation of cullin 3 with minimal effect on other cullin family members, making it an excellent probe compound for investigating the role of cullin 3 CRL in biological processes and human diseases. It also leads to NRF2 protein accumulation and transcriptional activation.

  • Binds to DCN1 and DCN2 with high affinity (Ki values of 12 nM and 10.4 nM respectively)
  • Shows >1000-fold selectivity over recombinant human DCN3-5 proteins
  • Disrupts the association of cellular DCN1 and UBC12 proteins
  • Increases mRNA levels of NQO1 and HO1
  • Used for research purposes only

ENCOMPASS_PREFERRED
3

Medchemexpress LLC VE-821 | 1232410-49-9 | 99.7% | 368.41 | 50 MG
SDP

VE-821 is a potent ATP-competitive inhibitor of ATR, with Ki/IC50 values of 13 nM/26 nM. It demonstrates excellent selectivity for ATR, showing minimal cross-reactivity against related PIKKs such as ATM, DNA-PK, mTOR, and PI3Kγ.

  • Shows minimal cross-reactivity against related PIKKs ATM, DNA-PK, mTOR, and PI3Kγ
  • Significantly enhances the sensitivity of PSN-1, MiaPaCa-2, and primary PancM pancreatic cancer cells to radiation and Gemcitabine
  • ATR inhibition by VE-821 leads to inhibition of radiation-induced G2/M arrest in cancer cells
  • Inhibits phosphorylation of Chk1 (Ser 345) in PSN-1 and MiaPaCa-2 cells after treatment with Gemcitabine, radiation, or both

ENCOMPASS_PREFERRED
4

Medchemexpress LLC VE-821 | 1232410-49-9 | 99.7% | 368.41 | 100 MG
SDP

VE-821 is a potent ATP-competitive inhibitor of ATR with Ki/IC50 values of 13 nM/26 nM. It exhibits excellent selectivity for ATR, demonstrating minimal cross-reactivity with related PIKKs like ATM, DNA-PK, mTOR, and PI3Kγ. This compound enhances the sensitivity of pancreatic cancer cells (PSN-1, MiaPaCa-2, and primary PancM) to radiation and Gemcitabine under both normoxic and hypoxic conditions. ATR inhibition by VE-821 also leads to the inhibition of radiation-induced G2/M arrest in cancer cells.

  • Potent ATP-competitive inhibitor of ATR (Ki/IC50 of 13 nM/26 nM)
  • Exhibits excellent selectivity for ATR with minimal cross-reactivity against related PIKKs
  • Enhances sensitivity of pancreatic cancer cells to radiation and Gemcitabine
  • Inhibits radiation-induced G2/M arrest in cancer cells
  • Inhibits phosphorylation of Chk1 (Ser 345) after specific treatments

ENCOMPASS_PREFERRED
5

Medchemexpress LLC VE-821 | 1232410-49-9 | 99.7% | 368.41 | 25 MG
SDP

VE-821 is a potent ATP-competitive inhibitor of ATR with a Ki/IC50 of 13 nM/26 nM. It demonstrates excellent selectivity for ATR with minimal cross-reactivity against related PIKKs such as ATM, DNA-PK, mTOR, and PI3Kγ. This inhibitor also significantly enhances the sensitivity of PSN-1, MiaPaCa-2, and primary PancM pancreatic cancer cells to radiation and Gemcitabine, under both normoxic and hypoxic conditions. ATR inhibition by VE-821 leads to the inhibition of radiation-induced G2/M arrest in cancer cells.

  • Potent ATP-competitive inhibitor of ATR
  • Ki/IC50 of 13 nM/26 nM for ATR
  • Demonstrates excellent selectivity for ATR with minimal cross-reactivity against related PIKKs
  • Enhances sensitivity of pancreatic cancer cells to radiation and Gemcitabine
  • Inhibits radiation-induced G2/M arrest in cancer cells
  • Inhibits phosphorylation of Chk1 (Ser 345)

ENCOMPASS_PREFERRED